» Articles » PMID: 34734364

Profiling of the Immune Landscape in Murine Glioblastoma Following Blood Brain/tumor Barrier Disruption with MR Image-guided Focused Ultrasound

Overview
Journal J Neurooncol
Publisher Springer
Date 2021 Nov 4
PMID 34734364
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Glioblastoma (GB) poses formidable challenges to systemic immunotherapy approaches owing to the paucity of immune infiltration and presence of the blood brain/tumor barriers (BBB/BTB). We hypothesize that BBB/BTB disruption (BBB/BTB-D) with focused ultrasound (FUS) and microbubbles (MB) increases immune infiltration in GB. As a prelude to rational combination of FUS with ITx, we herein investigate the impact of localized BBB/BTB-D on innate and adaptive immune responses in an orthotopic murine GB model.

Methods: Mice with GL261 gliomas received i.v. MB and underwent FUS BBB/BTB-D (1.1 MHz, 0.5 Hz pulse repetition frequency, 10 ms bursts, 0.4-0.6 MPa). Brains, meninges, and peripheral lymphoid organs were excised and examined by flow cytometry 1-2 weeks following FUS.

Results: The number of dendritic cells (DC) was significantly elevated in GL261 tumors and draining cervical LN in response to sonication. CD86 + DC frequency was also upregulated with 0.6 MPa FUS, suggesting increased maturity. While FUS did not significantly alter CD8 + T cell frequency across evaluated organs, these cells upregulated checkpoint molecules at 1 week post-FUS, suggesting increased activation. By 2 weeks post-FUS, we noted emergence of adaptive resistance mechanisms, including upregulation of TIGIT on CD4 + T cells and CD155 on non-immune tumor and stromal cells.

Conclusions: FUS BBB/BTB-D exerts mild, transient inflammatory effects in gliomas-suggesting that its combination with adjunct therapeutic strategies targeting adaptive resistance may improve outcomes. The potential for FUS-mediated BBB/BTB-D to modify immunological signatures is a timely and important consideration for ongoing clinical trials investigating this regimen in GB.

Citing Articles

Profile and clinical significance of SPARCL1 and its prognostic significance in breast cancer.

Xu X, Han Y, Song Y, Zhou Z, Chen S, Liu Y Oncol Lett. 2025; 29(4):196.

PMID: 40046638 PMC: 11880884. DOI: 10.3892/ol.2025.14942.


Pulsed focused ultrasound alters the proteomic profile of the tumor microenvironment in a syngeneic mouse model of glioblastoma.

Chen H, Koul D, Zhang Y, Ghobadi S, Zhu Y, Hou Q J Neurooncol. 2024; 170(2):347-361.

PMID: 39180641 DOI: 10.1007/s11060-024-04801-4.


Microbubble-Enhanced Focused Ultrasound for Infiltrating Gliomas.

Seas A, Malla A, Sharifai N, Winkles J, Woodworth G, Anastasiadis P Biomedicines. 2024; 12(6).

PMID: 38927437 PMC: 11200892. DOI: 10.3390/biomedicines12061230.


Focused Ultrasound Blood-Brain Barrier Opening Arrests the Growth and Formation of Cerebral Cavernous Malformations.

Fisher D, Sharifi K, Shah I, Gorick C, Breza V, Debski A bioRxiv. 2024; .

PMID: 38352349 PMC: 10862920. DOI: 10.1101/2024.01.31.577810.


Drug resistance in glioblastoma: from chemo- to immunotherapy.

Sharma S, Chepurna O, Sun T Cancer Drug Resist. 2024; 6(4):688-708.

PMID: 38239396 PMC: 10792484. DOI: 10.20517/cdr.2023.82.


References
1.
Curley C, Stevens A, Mathew A, Stasiak K, Garrison W, Miller G . Immunomodulation of intracranial melanoma in response to blood-tumor barrier opening with focused ultrasound. Theranostics. 2020; 10(19):8821-8833. PMC: 7392000. DOI: 10.7150/thno.47983. View

2.
McMahon D, Bendayan R, Hynynen K . Acute effects of focused ultrasound-induced increases in blood-brain barrier permeability on rat microvascular transcriptome. Sci Rep. 2017; 7:45657. PMC: 5379491. DOI: 10.1038/srep45657. View

3.
Lim M, Xia Y, Bettegowda C, Weller M . Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol. 2018; 15(7):422-442. DOI: 10.1038/s41571-018-0003-5. View

4.
Mead B, Kim N, Miller G, Hodges D, Mastorakos P, Klibanov A . Novel Focused Ultrasound Gene Therapy Approach Noninvasively Restores Dopaminergic Neuron Function in a Rat Parkinson's Disease Model. Nano Lett. 2017; 17(6):3533-3542. PMC: 5539956. DOI: 10.1021/acs.nanolett.7b00616. View

5.
Palucka A, Ueno H, Fay J, Banchereau J . Dendritic cells: a critical player in cancer therapy?. J Immunother. 2008; 31(9):793-805. PMC: 2716088. DOI: 10.1097/CJI.0b013e31818403bc. View